Pomona, New York — August 14, 2025 — NeuroLight, Inc., a pioneering neurotech company developing breakthrough neuromodulation solutions for sleep and neurological disorders, today announced the appointment of Dr. Jumaah I. Goldberg, DPT, MBA, as Chief Strategy Officer.
Dr. Goldberg joins NeuroLight as the company advances its proprietary brain state transfer technology, which enables the replication of optimal neural patterns from healthy individuals in those suffering from various disorders, with significant promise in addressing conditions such as insomnia, Alzheimer’s disease, Parkinson’s disease, PTSD, and cognitive decline.
Proven Leadership in Neuroscience Innovation
Dr. Goldberg brings extensive clinical and regulatory strategy experience translating complex neuroscience products into commercial success. Throughout her career, she has launched nine neuroscience assets spanning pharmaceuticals, neuromodulation devices, and software-as-a-medical-device (SaMD) across multiple sclerosis (MS), Alzheimer’s disease, and stroke. As Vice President, Strategy Consulting at Lumanity, Dr. Goldberg has enhanced strategic readiness and operational agility for companies entering rare neurological disease and other neuroscience markets. At Ipsen, she shaped neuroscience portfolio strategy as Head of US Medical Affairs-Neuroscience, earning Innovator of the Year in 2023. Prior to that she launched Floodlight MS, a first-in-class SaMD, at Genentech and held strategic positions at Sanofi/Genzyme, Biogen, and Novartis.
Advancing NeuroLight’s Mission
“Dr. Goldberg’s deep expertise in neuroscience, neuromodulation and neurodegenerative diseases, combined with her proven ability to bring innovative technologies to market, makes her an invaluable addition to our leadership team,” said Alexander Poltorak, Founder and President of NeuroLight. “Her strategic vision will be instrumental as we advance our technology toward commercialization. We are delighted to welcome Dr. Goldberg to the NeuroLight team.”
“There remains a tremendous unmet need in neurodegenerative diseases, with growing evidence linking sleep cycle dysfunction to pre-symptomatic disease phases,” said Dr. Goldberg. “NeuroLight’s non-invasive neuromodulation approach offers a promising new avenue to address both sleep disorders and neurodegenerative diseases through targeted brain state optimization. I’m thrilled to contribute to advancing this innovative technology and energized by the hope it may bring to patients and families affected by these challenging conditions.”
Revolutionary Technology Platform
NeuroLight’s flagship product, the NeuroMask™ smart sleep mask, uses proprietary sensory neuromodulation combining precisely calibrated light and sound patterns to induce specific brain states—from deep sleep stages (N3, slow-wave sleep, REM) to peak performance states. The technology offers a non-pharmaceutical approach to treating and potentially preventing neurological conditions.
The company is pursuing a multi-stage commercialization strategy, targeting both wellness and medical device markets to accelerate access while building clinical evidence for therapeutic applications.